Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Ebanga™: The Most Recent Fda-Approved Drug for Treating Ebola Publisher



Taki E1 ; Ghanavati R2 ; Navidifar T3 ; Dashtbin S4, 5 ; Heidary M6, 7 ; Moghadamnia M8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Faculty of Medical Sciences, Behbahan, Behbahan, Iran
  3. 3. Department of Basic Sciences, Shoushtar Faculty of Medical Sciences, Shoushtar, Iran
  4. 4. Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  5. 5. Microbial Biotechnology Research Center, Iran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Laboratory Sciences, School of Paramedical Sciences, Sabzevar University of Medical Sciences, Sabzevar, Iran
  7. 7. Leishmaniasis Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
  8. 8. Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Source: Frontiers in Pharmacology Published:2023


Abstract

Ebolavirus (EBOV) is a virulent pathogen that causes Ebola virus disease (EVD), which is a life-threatening human condition with a fatality rate of up to 90%. Since the first outbreak in Africa in 1976, several outbreaks and epidemics of EBOV have occurred across the globe. While EVD is recognized as a serious threat to human health and outbreaks occur almost every year, the treatment options for the disease are limited. In designing therapeutic strategies against EBOV infection, viral structural proteins, such as glycoprotein (GP), could be an excellent target for neutralizing the virus. According to the latest research, GP-specific antibodies are the most efficient post-exposure treatments for EVD. Ansuvimab-zykl, i.e., mAb114 (Ebanga™), is a recent FDA-approved human immunoglobulin monoclonal antibody targeting EBOV GP. This review provides a brief overview of the pharmacological effects and safety profile of ansuvimab in clinical trials and provides insights into the precise mechanism of this new drug for treating EVD. Copyright © 2023 Taki, Ghanavati, Navidifar, Dashtbin, Heidary and Moghadamnia.
Related Docs
1. Ebola Virus Disease: A Narrative Review, Microbial Pathogenesis (2023)
2. Convalescent Plasma Against Covid-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious Diseases, Microorganisms (2020)
3. Recent Advances in Antibody-Based Immunotherapy Strategies for Covid-19, Journal of Cellular Biochemistry (2021)
4. Natural Killer Cells and Their Exosomes in Viral Infections and Related Therapeutic Approaches: Where Are We?, Cell Communication and Signaling (2023)
5. An Overview of the Role of Niemann-Pick C1 (Npc1) in Viral Infections and Inhibition of Viral Infections Through Npc1 Inhibitor, Cell Communication and Signaling (2023)
Experts (# of related papers)
Hanieh-Sadat Ejtahed (1)